40 research outputs found
Π Π°Π΄ΠΈΠΎΠΌΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· Π΄Π»Ρ ΠΎΠ±ΡΠ΅ΠΊΡΠΈΠ²ΠΈΠ·Π°ΡΠΈΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΈ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ Π³Π»ΠΈΠΎΠ±Π»Π°ΡΡΠΎΠΌΡ
Introduction. Glioblastoma is a neuroepithelial malignant brain tumour of predominantly astrocytic origin with an aggressive course and an extremely unfavorable prognosis. Since the median of overall survival with glioblastoma is 14.6 months after complex treatment that includes a combination of surgical treatment, radiation therapy and chemotherapy, the development a personalized approach in the diagnosis and treatment of glioblastomas is appeared to be urgent.Materials and methods. MRIs of a patient undergoing chemoradiotherapy for glioblastoma G4 were performed on the following MRI scanners: Philips Ingenia 1.5T and Philips Ingenia Ambient 1.5T. The analysis of MR-images was carried out using the Matlab 2021 apps.Results and discussion. MR-images were analyzed before and after surgery, and after a course of chemoradiotherapy. The statistical characteristics of the local brightness distribution of the lesion image, which are described by statistical texture parameters, were analyzed as informative features of the lesion area on the images. Initial confirmation of the ability to objectify diagnosis and treatment using the above statistical parameters of T2 MR images of lesion area has been obtained.Conclusion. The aim of further research in this area is to use radiomic study for planning and monitoring the treatment of high-grade gliomas, estimate disease outcomes, and analyze the response to complex treatments in a predictive way.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠ»ΠΈΠΎΠ±Π»Π°ΡΡΠΎΠΌΠ° β Π½Π΅ΠΉΡΠΎΡΠΏΠΈΡΠ΅Π»ΠΈΠ°Π»ΡΠ½Π°Ρ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½Π°Ρ ΠΎΠΏΡΡ
ΠΎΠ»Ρ Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ Π°ΡΡΡΠΎΡΠΈΡΠ°ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΠΈΡΡ
ΠΎΠΆΠ΄Π΅Π½ΠΈΡ Ρ Π°Π³ΡΠ΅ΡΡΠΈΠ²Π½ΡΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΈ ΠΊΡΠ°ΠΉΠ½Π΅ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΎΠΌ. ΠΠ΅Π΄ΠΈΠ°Π½Π° ΠΎΠ±ΡΠ΅ΠΉ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ ΠΏΡΠΈ Π³Π»ΠΈΠΎΠ±Π»Π°ΡΡΠΎΠΌΠ΅ ΡΠΎΡΡΠ°Π²Π»ΡΠ΅Ρ 14,6 ΠΌΠ΅ΡΡΡΠ° ΠΏΠΎΡΠ»Π΅ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ, Π²ΠΊΠ»ΡΡΠ°ΡΡΠ΅Π³ΠΎ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΡ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ, Π»ΡΡΠ΅Π²ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ, ΡΡΠΎ Π΄ΠΈΠΊΡΡΠ΅Ρ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΠΏΠ΅ΡΡΠΎΠ½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Π° Π² Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π³Π»ΠΈΠΎΠ±Π»Π°ΡΡΠΎΠΌ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: ΠΠ Π’-ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°, ΠΏΡΠΎΡ
ΠΎΠ΄ΠΈΠ²ΡΠ΅Π³ΠΎ Ρ
ΠΈΠΌΠΈΠΎΠ»ΡΡΠ΅Π²ΠΎΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎ ΠΏΠΎΠ²ΠΎΠ΄Ρ Π³Π»ΠΈΠΎΠ±Π»Π°ΡΡΠΎΠΌΡ G4, Π²ΡΠΏΠΎΠ»Π½ΡΠ»ΠΈΡΡ Π½Π° Π°ΠΏΠΏΠ°ΡΠ°ΡΠ°Ρ
: ΠΌΠ°Π³Π½ΠΈΡΠ½ΠΎ-ΡΠ΅Π·ΠΎΠ½Π°Π½ΡΠ½ΡΠΉ ΡΠΎΠΌΠΎΠ³ΡΠ°Ρ Philips Ingenia 1.5T ΠΈ Philips IngeniΠ° Πmbition 1,5 Π’. ΠΠ½Π°Π»ΠΈΠ· ΠΠ Π’-ΠΈΠ·ΠΎΠ±ΡΠ°ΠΆΠ΅Π½ΠΈΠΉ ΠΎΡΡΡΠ΅ΡΡΠ²Π»Π΅Π½ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΏΠ°ΠΊΠ΅ΡΠ° ΠΏΡΠΈΠΊΠ»Π°Π΄Π½ΡΡ
ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌ Matlab 2021.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ ΠΠ Π’-ΠΈΠ·ΠΎΠ±ΡΠ°ΠΆΠ΅Π½ΠΈΡ Π΄ΠΎ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π²ΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΡΡΠ²Π°, ΠΏΠΎΡΠ»Π΅ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π²ΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΡΡΠ²Π° ΠΈ ΠΏΠΎΡΠ»Π΅ ΠΊΡΡΡΠ° Ρ
ΠΈΠΌΠΈΠΎΠ»ΡΡΠ΅Π²ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ. Π ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠ²Π½ΡΡ
ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ² ΠΎΡΠ°Π³ΠΎΠ² ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ Π½Π° ΠΈΠ·ΠΎΠ±ΡΠ°ΠΆΠ΅Π½ΠΈΡΡ
ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠΈ Π»ΠΎΠΊΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΡΡΠΊΠΎΡΡΠΈ ΠΈΠ·ΠΎΠ±ΡΠ°ΠΆΠ΅Π½ΠΈΡ ΠΎΡΠ°Π³Π° ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΎΠΏΠΈΡΡΠ²Π°ΡΡΡΡ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΡΠ΅ΠΊΡΡΡΡΠ½ΡΠΌΠΈ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠ°ΠΌΠΈ.ΠΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. ΠΠΎΠ»ΡΡΠ΅Π½ΠΎ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠ΅ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½ΠΈΠ΅ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΎΠ±ΡΠ΅ΠΊΡΠΈΠ²ΠΈΠ·Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠ° Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠΎ ΡΠΊΠ°Π·Π°Π½Π½ΡΠΌ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠ°ΠΌ Π’2 ΠΠ Π’-ΠΈΠ·ΠΎΠ±ΡΠ°ΠΆΠ΅Π½ΠΈΠΉ ΠΎΡΠ°Π³ΠΎΠ² ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π¦Π΅Π»ΡΡ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π² Π΄Π°Π½Π½ΠΎΠΌ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΠΈ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΠ°Π΄ΠΈΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° Π΄Π»Ρ ΠΏΠ»Π°Π½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ, ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π° Π»Π΅ΡΠ΅Π½ΠΈΡ Π³Π»ΠΈΠΎΠΌ Π²ΡΡΠΎΠΊΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΡΡΠΈ, Π΄Π»Ρ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈΡΡ
ΠΎΠ΄ΠΎΠ² Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° ΠΎΡΠ²Π΅ΡΠ° Π½Π° ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΠ΅
The prevalence of renal dysfunction in patients with coronary heart disease, coronary artery bypass surgery
Relevance. Despite the successes achieved in the treatment of coronary heart disease through the use of high-tech surgical methods of treatment, including coronary bypass surgery, the evaluation of the postoperative course of the disease, the search for facts affecting the progression of early and late cardiovascular complications remain relevant. Identifying early predictors of adverse outcomes is a critical task. The presence of renal dysfunction in the postoperative period after coronary artery bypass surgery is an important factor leading to a deterioration of the cardiorenal relationship. Purpose of the study. To assess the prevalence of renal dysfunction among patients with coronary heart disease in the postoperative period after coronary artery bypass surgery in conjunction with other cardiovascular risk factors.ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ. ΠΠ΅ΡΠΌΠΎΡΡΡ Π½Π° ΡΡΠΏΠ΅Ρ
ΠΈ, Π΄ΠΎΡΡΠΈΠ³Π½ΡΡΡΠ΅ Π² ΠΏΠ΅ΡΠ΅Π½ΠΈΠΈ ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΡΠ΅ΡΠ΄ΡΠ° Π±Π»Π°Π³ΠΎΠ΄Π°ΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ Π²ΡΡΠΎΠΊΠΎΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ½ΡΡ
Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² Π»Π΅ΡΠ΅Π½ΠΈΡ, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ, Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΠΌΠΈ ΠΎΡΡΠ°ΡΡΡΡ Π²ΠΎΠΏΡΠΎΡΡ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΏΠΎΡΠΏΠ΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, ΠΏΠΎΠΈΡΠΊ ΡΠ°ΠΊΡΠΎΠ², Π²Π»ΠΈΡΡΡΠΈΡ
Π½Π° ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ°Π½Π½ΠΈΡ
ΠΈ ΠΏΠΎΠ·Π΄Π½ΠΈΡ
ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ. ΠΡΡΠ²Π»Π΅Π½ΠΈΠ΅ ΡΠ°Π½Π½ΠΈΡ
ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΎΡΠΎΠ² Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΡ
ΠΈΡΡ
ΠΎΠ΄ΠΎΠ² ΡΠ²Π»ΡΠ΅ΡΡΡ Π²Π°ΠΆΠ½Π΅ΠΉΡΠ΅ΠΉ Π·Π°Π΄Π°ΡΠ΅ΠΉ. ΠΠ°Π»ΠΈΡΠΈΠ΅ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΠΈ ΠΏΠΎΡΠ΅ΠΊ Π² ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ ΠΏΠΎΡΠ»Π΅ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ²ΠΏΡΠ΅ΡΡΡ Π²Π°ΠΆΠ½ΡΠΌ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ, ΠΏΡΠΈΠ²ΠΎΠ΄ΡΡΠΈΠΌ ΠΊ ΡΡ
ΡΠ΄ΡΠ΅Π½ΠΈΡ ΠΊΠ°ΡΠ΄ΠΈΠΎΡΠ΅Π½Π°Π»ΡΠ½ΡΡ
Π²Π·Π°ΠΈΠΌΠΎΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΉ. Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. ΠΡΠ΅Π½ΠΈΡΡ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΡ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΠΈ ΠΏΠΎΡΠ΅ΠΊ ΡΡΠ΅Π΄ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ ΡΠ΅ΡΠ΄ΡΠ° Π² ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ ΠΏΠΎΡΠ»Π΅ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π²ΠΎ Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·ΠΈ Ρ Π΄ΡΡΠ³ΠΈΠΌΠΈ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌΠΈ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠ³ΠΎ ΡΠΈΡΠΊΠ°
Genesis of active phase in MoW/Al2O3 hydrotreating catalysts monitored by HAADF and in situ QEXAFS combined to MCR-ALS analysis
Alumina supported MoW hydrotreating catalyst was synthesized by using bimetallic H-4[SiMo3W9O40] Keggin heteropolyacid (HPA). Catalysts based on monometallic H-4[SiMo3W9O40] and H-4[SiMo3W9O40] and their mixture were also studied. Genesis of the active phase was studied during atmospheric gas sulfidation by H2S/H-2 of the catalysts by in-situ Quick X-ray absorption spectroscopy (XAS) and High-Angle Annular Dark-Field (HAADF) imaging. The combination of different chemometric tools such as Principal Component Analysis (PCA) and Multivariate Curve Resolution with Alternating Least Squares (MCR-ALS) allowed to determine the number of intermediate species, their chemical nature and concentration profiles during sulfidation. It was found that tungsten sulfidation using bimetallic HPA precursor started at lower temperature, compared to W sulfidation in the monometallic and in the mixture of monometallic HPA catalysts. Simultaneous sulfidation of Mo and W atoms in case of the bimetallic molecular precursor can govern the formation of mixed MoWS2 phase, which formation during activation was evidenced by HAADF